If it weren’t for the traffic along South MacDill Avenue, Javonne Mansfield swears you could hear the sizzle of a frying pan.
Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year
Seven months after Nimbus Therapeutics sold an experimental autoimmune disease medicine to Takeda Pharmaceuticals for up to $6 billion, the Boston biotech said Wednesday it has raised